Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | HTR3A | P46098 | 4/20 | 0.53 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.53 |
| ▸ | HTR3B | O95264 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.50 |
| ▸ | HTR6 | P50406 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4332133 | 0.84 | AOC3 (0.55) | AOC3KCNH2HTR2CHTR3AHTR3E | |
| SCHEMBL13193690 | 0.82 | HTR3E (0.55) | AOC3HTR2CHTR3AHTR3EHTR3B | |
| SCHEMBL13751510 | 0.81 | HTR3E (0.58) | AOC3HTR2CHTR3AHTR3EHTR3B | |
| SCHEMBL16848670 | 0.79 | AOC3 (0.73) | AOC3HTR2CHTR3AHTR3EHTR3B | |
| SCHEMBL1433649 | 0.79 | AOC3 (1.00) | AOC3HTR3AHTR3EHTR3BALDH1A1 | |
| Hydrochloric Acid SCHEMBL1432753 | 0.78 | AOC3 (0.98) | AOC3HTR3AHTR3EHTR3BALDH1A1 | |
| SCHEMBL25189276 | 0.78 | HTR3E (0.58) | AOC3HTR2CHTR3AHTR3EHTR3B | |
| SCHEMBL5217823 | 0.78 | ALDH1A1 (0.58) | AOC3HTR2CHTR3AHTR3EHTR3B | |
| SCHEMBL603395 | 0.78 | HRH4 (0.56) | AOC3HTR2CHTR3AUSP2ADRB1 | |
| SCHEMBL13171621 | 0.75 | HTR3E (0.54) | AOC3HTR2CHTR3AHTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335907-B1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB PUBL (SE) | 2010-06-09 | — | — | EP | disclosed |
| CN-1329389-C | Novel compounds and their use | BIOVITRUM AB (SE) | 2007-08-01 | — | — | CN | disclosed |
| US-7247633-B2 | Pyrimidine compounds and their use | BIOVITRUM AB (SE) | 2007-07-24 | — | — | US | disclosed |
| US-7229997-B2 | Compounds and their use | BIOVITRUM AB (SE) | 2007-06-12 | — | — | US | disclosed |
| EP-1506185-B1 | COMPOUNDS AND THEIR USE AS INHIBITORS OF 5-HT | BIOVITRUM AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| CN-1701068-A | Novel compounds and their use | BIOVITRUM AB (SE) | 2005-11-23 | — | — | CN | disclosed |
| EP-1506185-A1 | NOVEL COMPOUNDS AND THEIR USE | Biovitrum AB (SE) | 2005-02-16 | — | — | EP | disclosed |
| US-20040014767-A1 | Novel compounds and their use | BIOVITRUM AB, A SWEDISH CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20030232814-A1 | Novel compounds and their use | BIOVITRUM AB (PUBL) (SE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003097636-A1 | NOVEL COMPOUNDS AND THEIR USE | BIOVITRUM AB (SE) | 2003-11-27 | — | — | WO | disclosed |
| EP-1335907-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| US-6593330-B2 | Central nervous system disorders; antiserotonine agents | BIOVITRUM (SE) | 2003-07-15 | — | — | US | disclosed |
| US-20020147200-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-10-10 | — | — | US | disclosed |
| WO-2002040456-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232814-A1 | Novel compounds and their use | GPR119, FABP4, MC4R | AOC3 2038/4885KCNH2 3865/4885HTR2C 233/4885 |
| US-20020147200-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | AOC3 3418/4885KCNH2 2992/4885HTR2C 916/4885 |
| US-20040014767-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | AOC3 3418/4885KCNH2 2992/4885HTR2C 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.